Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Reliance, Inc. reports Q3 results on October 21 with the analyst community just adding a new voice to the debate and short sellers building positions at the fastest monthly pace in months, even as the stock trades within reach of its all-time high.
The most notable development this week came from the Street. Barclays initiated coverage on Wednesday with an Equal-Weight rating and a $420 target, adding institutional weight to a consensus that has been drifting cautiously constructive. JP Morgan raised its target to $400 from $390 earlier in the week, though it held its Neutral rating. Keybanc, the only outright bull in recent changes, nudged its Overweight target up to $421. The mean target across the group stands at $412, a thin premium to the current price of $404. That spread suggests analysts broadly see the stock as fairly valued here rather than cheap, and the Hold consensus reflects that equilibrium. EPS momentum factor scores, sitting at 65 on a 30-day view and 83 on a 90-day horizon, tell a stronger story: the company has been beating estimates consistently, ranking in the 74th percentile on EPS surprise. The dividend score, at 95, is a standout. Valuation multiples are more measured, with a trailing P/E near 16.8x and an EV/EBITDA of 11.4x, both ticking modestly higher over the past month as the stock has recovered.
Short interest deserves attention because of the pace of change, not the absolute level. At 2.4% of the free float, bears have no grip on this name. But that figure is up 30% over the past month, the bulk of the jump arriving in a single step around October 7 to 8. It is a small absolute position but the acceleration is visible enough to notice heading into a print. Borrowing costs have moved in the opposite direction, falling around 15% over the week to just 0.31%, one of the lowest readings of the past six weeks. Availability in the lending pool is exceptionally loose, with over 9,400% availability, meaning roughly 36 million shares remain available to borrow against what is currently lent out. There is no friction in the borrow market at all. The ORTEX short score, at 34.8, is in the 40th percentile and has moved only marginally over the past two weeks, reinforcing the picture of a low-conviction short position rather than a building bear thesis.
Options positioning has edged slightly more cautious ahead of the print. The put/call ratio has climbed to 0.33, roughly 1.6 standard deviations above its 20-day average of 0.30. That is not an extreme reading by any historical standard: the 52-week low touched 0.18 and the high reached 1.02, so the current level sits close to the lower end of the range. The modest elevation does suggest some hedging into earnings, but it falls well short of the kind of defensive positioning that would signal serious concern. Calls still dominate the options mix by a wide margin.
The two most recent earnings prints both produced positive single-day reactions. The Q2 result in July moved the stock just over 3% on the day, extending to more than 5% over the following week. Peers NUE and STLD both rose modestly on the week, up around 1% each, with CLF showing stronger momentum at nearly 5% weekly gain. Reliance's 0.6% weekly gain is consistent with the group but trails the more cyclically geared names, which may reflect the market pricing in a steady rather than spectacular quarter for the metals service center model.
Institutional ownership is stable and heavily indexed. BlackRock holds 11.4% as of September 30, the largest single block, with a modest addition of around 72,000 shares in the period. State Street added roughly 99,000 shares in the same window. There are no 13D activist filings on the register. The activist holders page shows only passive 13G filers, and the disclosure note applies: stakes are as-last-disclosed around the 5% threshold. On the insider side, the 90-day net is negative at roughly $2.5 million in open-market sales, led by CFO Arthur Ajemyan's $902,000 sale in late July at $410. None of the sales were under a 10b5-1 plan, though the scale is modest relative to the company's size and the stock has largely recovered to those price levels.
The October 21 print is the thing to watch. With the analyst consensus freshly updated, a thin price-target premium, SI accelerating from a low base, and options showing mild pre-earnings hedging, the setup is attentive rather than polarised.
See the live data behind this article on ORTEX.
Open RS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
